ECSP099738A - Derivados de pirazolona como inhibidores de pde4 - Google Patents

Derivados de pirazolona como inhibidores de pde4

Info

Publication number
ECSP099738A
ECSP099738A EC2009009738A ECSP099738A ECSP099738A EC SP099738 A ECSP099738 A EC SP099738A EC 2009009738 A EC2009009738 A EC 2009009738A EC SP099738 A ECSP099738 A EC SP099738A EC SP099738 A ECSP099738 A EC SP099738A
Authority
EC
Ecuador
Prior art keywords
pirazolona
derivatives
pde4 inhibitors
inhibitors
phosphodiesterase
Prior art date
Application number
EC2009009738A
Other languages
English (en)
Inventor
Christian Scheufler
Armin Hatzelmann
Beate Schmidt
Juergen Volz
Martin P Feth
Rolf-Peter Hummel
Christof Zitt
Andrea Wohlsen
Degenhard Marx
Hans-Peter Kley
Deborah Ockert
Anke Heuser
Johannes A M Christiaans
Geert Jan Sterk
Wiro M P B Menge
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of ECSP099738A publication Critical patent/ECSP099738A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)

Abstract

Los compuestos de cierta fórmula (1), en los cuales R1, R7, R8, R9 y n tienen los significados que se les dan en la descripción, y son inhibidores novedosos efectivos de la fosfodiesterasa de tipo 4.
EC2009009738A 2007-05-16 2009-11-13 Derivados de pirazolona como inhibidores de pde4 ECSP099738A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07108314 2007-05-16
PCT/EP2008/055867 WO2008138939A1 (en) 2007-05-16 2008-05-14 Pyrazolone derivatives as pde4 inhibitors

Publications (1)

Publication Number Publication Date
ECSP099738A true ECSP099738A (es) 2009-12-28

Family

ID=38179942

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009738A ECSP099738A (es) 2007-05-16 2009-11-13 Derivados de pirazolona como inhibidores de pde4

Country Status (30)

Country Link
US (3) US8304436B2 (es)
EP (3) EP2402330B1 (es)
JP (2) JP5529010B2 (es)
KR (1) KR101601284B1 (es)
CN (2) CN101657441B (es)
AR (1) AR066576A1 (es)
AT (1) ATE526326T1 (es)
AU (1) AU2008250069B2 (es)
BR (1) BRPI0811214A2 (es)
CA (1) CA2686909C (es)
CO (1) CO6220956A2 (es)
CY (1) CY1112152T1 (es)
DK (1) DK2148876T3 (es)
EA (1) EA018984B1 (es)
EC (1) ECSP099738A (es)
ES (2) ES2427442T3 (es)
HR (1) HRP20110940T1 (es)
IL (1) IL201959A (es)
ME (1) ME00952B (es)
MX (1) MX2009012062A (es)
MY (1) MY154498A (es)
NZ (1) NZ581547A (es)
PL (1) PL2148876T3 (es)
PT (1) PT2148876E (es)
RS (1) RS52074B (es)
SI (1) SI2148876T1 (es)
TW (2) TWI414521B (es)
UA (1) UA100019C2 (es)
WO (1) WO2008138939A1 (es)
ZA (1) ZA200906423B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101601284B1 (ko) * 2007-05-16 2016-03-08 다케다 게엠베하 Ｐｄｅ4 억제제로서 피라졸론 유도체
AR074318A1 (es) * 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
US8889674B2 (en) * 2009-03-05 2014-11-18 Shionogi & Co., Ltd. Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism
WO2011136752A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
JP5609614B2 (ja) * 2010-12-15 2014-10-22 東ソー株式会社 新規アリールアミンデンドリマー状化合物、その製造方法およびその用途
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2903460A (en) * 1956-04-07 1959-09-08 Sandoz Ag Pyrazolone derivatives
US4550119A (en) 1983-05-23 1985-10-29 Warner-Lambert Company 2,4-Dihydro-5-[(substituted)phenyl]-4,4-disubstituted-3H-pyrazol-3-ones
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
EP0652868B1 (en) 1992-07-28 2004-11-10 Aventis Pharma Limited INHIBITORS OF c-AMP PHOSPHODIESTERASE
CN1046939C (zh) 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
EP0772610B9 (de) 1994-07-22 2001-07-25 Byk Gulden Lomberg Chemische Fabrik GmbH Dihydrobenzofurane
CZ293815B6 (cs) * 1997-01-15 2004-08-18 Altanaápharmaáag Ftalazinonové deriváty
US6418201B1 (en) 2000-02-22 2002-07-09 Intel Corporation Multiple platform voice processing system with optimized resource allocation
JP4301812B2 (ja) * 2001-02-15 2009-07-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしてのフタラインオン−ピペリジノ−誘導体
JP2004527545A (ja) * 2001-04-20 2004-09-09 ファイザー・プロダクツ・インク １，３−置換インデンおよびアリール縮合アザ多環式化合物の調製方法
SK14342003A3 (sk) 2001-04-25 2004-05-04 Altana Pharma Ag Ftalazinóny, farmaceutický prostriedok s ich obsahom a ich použitie
WO2004018449A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
EP1556369A1 (en) * 2002-08-10 2005-07-27 ALTANA Pharma AG Pyridazinone-derivatives as pde4 inhibitors
DE60313472T2 (de) * 2002-08-10 2008-01-24 Nycomed Gmbh Pyrrolidindion-substituierte piperidin-phthalazone als pde4-inhibitoren
CA2496732A1 (en) * 2002-08-20 2004-03-04 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
AR045536A1 (es) * 2003-08-29 2005-11-02 Ranbaxy Lab Ltd Inhibidores de la fosfodiesterasa tipo -iv
EP1720854A1 (en) 2004-02-04 2006-11-15 Altana Pharma AG Phthalzinone derivatives as pde4 inhibitors
EP1716133B1 (en) * 2004-02-04 2008-03-26 Nycomed GmbH 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
JP2006169138A (ja) * 2004-12-14 2006-06-29 Kyorin Pharmaceut Co Ltd ピラゾロピリジンピラゾロン誘導体とその付加塩及びｐｄｅ阻害剤
KR101601284B1 (ko) * 2007-05-16 2016-03-08 다케다 게엠베하 Ｐｄｅ4 억제제로서 피라졸론 유도체

Also Published As

Publication number Publication date
US9090597B2 (en) 2015-07-28
CA2686909A1 (en) 2008-11-20
JP5529010B2 (ja) 2014-06-25
HK1191574A1 (zh) 2014-08-01
WO2008138939A1 (en) 2008-11-20
AU2008250069A1 (en) 2008-11-20
SI2148876T1 (sl) 2012-01-31
EP2148876B1 (en) 2011-09-28
TW200914439A (en) 2009-04-01
ZA200906423B (en) 2010-06-30
TWI414521B (zh) 2013-11-11
HK1141017A1 (en) 2010-10-29
AR066576A1 (es) 2009-08-26
EP2148876A1 (en) 2010-02-03
KR20100017745A (ko) 2010-02-16
EA200901504A1 (ru) 2010-04-30
IL201959A (en) 2015-04-30
US20100120757A1 (en) 2010-05-13
US20130012544A1 (en) 2013-01-10
RS52074B (sr) 2012-06-30
PT2148876E (pt) 2011-12-28
US8304436B2 (en) 2012-11-06
MY154498A (en) 2015-06-30
NZ581547A (en) 2012-02-24
CA2686909C (en) 2016-07-05
EA018984B1 (ru) 2013-12-30
CN101657441A (zh) 2010-02-24
US8865745B2 (en) 2014-10-21
US20140378509A1 (en) 2014-12-25
AU2008250069B2 (en) 2013-07-25
JP2010526852A (ja) 2010-08-05
EP2402330B1 (en) 2013-06-26
JP2014159452A (ja) 2014-09-04
KR101601284B1 (ko) 2016-03-08
IL201959A0 (en) 2010-06-16
DK2148876T3 (da) 2012-01-16
CN103463086B (zh) 2015-10-21
EP2508520A1 (en) 2012-10-10
EP2402330A1 (en) 2012-01-04
BRPI0811214A2 (pt) 2014-10-29
ES2427442T3 (es) 2013-10-30
ES2374337T3 (es) 2012-02-15
MX2009012062A (es) 2009-11-19
CN101657441B (zh) 2013-09-11
ATE526326T1 (de) 2011-10-15
HRP20110940T1 (hr) 2012-01-31
UA100019C2 (en) 2012-11-12
CO6220956A2 (es) 2010-11-19
CN103463086A (zh) 2013-12-25
ME00952B (me) 2012-06-20
PL2148876T3 (pl) 2012-02-29
TWI460174B (zh) 2014-11-11
JP5850972B2 (ja) 2016-02-03
TW201406752A (zh) 2014-02-16
CY1112152T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
UY39128A (es) Composiciones y métodos para modular la senda de señalización de wnt
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CO6551705A2 (es) Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina
CR9786A (es) Compuestos de bencimidazol-tiofeno
CR11548A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
CR11454A (es) Derivados de isoxazolo-piridina
UY36907A (es) Nuevas carboxamidas de acción microbiocida
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
ECSP11010898A (es) Pirrolidina-2-carboxamidas sustituidas
ECSP088558A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
UY31562A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31563A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31560A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
CR20140135A (es) Nuevos derivados de aril-quinolina
MX379353B (es) Compuesto de piperidina tipo quinoxalina sustituida y uso de los mismos.
EA201070519A1 (ru) Соединения тропана
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
ECSP099738A (es) Derivados de pirazolona como inhibidores de pde4
ECSP10010425A (es) Pirrolopirimidincarboxamidas
GT200600117A (es) Nuevos compuestos farmaceuticos
UY29486A1 (es) Compuestos utiles en terapia
CR8205A (es) Derivados de nicotinamida utiles como inhibidores de pde4